Dietmar Siemann, PhD
Email:siemadw@ufl.edu
Phone: 352-265-0316
Fax: 352-265-0759
Dr. Siemann is Professor and Associate Chairman for Research in the Department of Radiation Oncology at the University of Florida. He holds an endowed chair as the John P. Cofrin Professor for Research in Radiation Oncology. Dr. Siemann carries out laboratory research in cancer biology. Specifically, he specializes in translational research. He investigates ways to make cancer cells more vulnerable to the proven cancer treatments such as radiation therapy and drug therapy. He works with a team of cancer specialists to put such enhancers to work in cancer clinical trials.
Education:
* University of Manitoba, B.Sc. (Honors), 1972, Physics
* University of Toronto, M.Sc., 1975, Medical Biophysics
* University of Toronto, Ph.D., 1977, Medical Biophysics
* University of Rochester, Postdoctoral studies, 1977-78, Radiobiology
Professional Experience
* 7/1/98 - present: John P. Cofrin Professor for Research in Radiation Oncology, Department of Radiation Oncology, University of Florida, Gainesville
* 7/1/95 - present: Professor and Associate Chair for Research, Department of Radiation Oncology, University of Florida College of Medicine, Gainesville
* 2/1/96 - present: Professor, Department of Pharmacology and Therapeutics, University of Florida College of Medicine, Gainesville
* 1/1/92 - 6/30/95: Professor and Associate Chair for Research, Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry
* 8/1/88 - 6/30/95: Head of the Tumor Biology Division (formerly Experimental Therapeutics Division), University of Rochester Cancer Center
* 1/1/95 - 6/30/95: Professor, Environmental Medicine, University of Rochester School of Medicine
* 7/1/85 - 12/31/91: Associate Professor of Radiation Oncology and of Oncology in Biophysics, University of Rochester School of Medicine and Dentistry
* 8/1/88 - 12/31/91: Head of the Division of Radiation Biology, Department of Radiation Oncology, University of Rochester School of Medicine and Dentistry
* 4/1/84 - 7/31/88: Assistant Director, Experimental Therapeutics Division, University of Rochester Cancer Center
* 7/1/81 - 6/30/85: Assistant Professor, Radiation Biology and Biophysics, University of Rochester School of Medicine and Dentistry
* 1/1/80 - 06/30/85: Assistant Professor, Radiation Oncology in Radiology, University of Rochester School of Medicine and Dentistry
* 10/1/78 - 12/31/79: Senior Instructor, Radiation Oncology in Radiology, University of Rochester School of Medicine and Dentistry
Recent Publications (from a total of 150)
* Shi, W., Siemann D.W. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor. Br J Cancer. 2002 Jul 1; 87(1):119-126.
* [Abstract] Shi W., Teschendorf C., Muzyczka N., Siemann D.W. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Therapy. 2002 Jun; 9(6):513-521. [Abstract]
* Siemann D.W., Rojanni A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 2002 mAY 1; 53(1):164-171
* [Abstract] Brown J.M., Siemann D.W. The 93rd Annual Meeting of the American Association for Cancer Research. April 6-10 2002, San Francisco, CA. Expert Opin Pharmacother. 2002 May; 3(5):629-632.
* [Abstract] Rojiani A.M., Li L., Rise L., Siemann D.W. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-assiciated Kaposi's sarcoma. Acta. Oncol. 2002; 41(1):98-105.
* [Abstract] Li L., Rojiani A.M., Siemann D.W. Preclinical evaluation of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol. 2002; 41(1):91-97.
* [Abstract] Siemann D.W., Mercer E., Lepler S., Rojiani A.M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer. 2002 May 1;99(1):1-6.